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Abstract: Cystoid macular edema in its various forms can be considered one of the leading 
causes of central vision loss in the developed world. It occurs in a wide variety of pathologic 
conditions and represents the final common pathway of several basic processes. Therapeutic 
approaches to cystoid macular edema depend on a clear understanding of its contributing 
pathophysiologic mechanisms. This review will discuss the mechanism of ocular inflammation 
in cystoid macular edema with a particular focus on the inflammatory causes: post-operative, 
uveitic, and after laser procedures. A variety of pharmacologic agents targeting inflammatory 
molecules have been shown to reduce macular edema and improve visual function. However, 
the long-term efficacy and safety of most new therapies have yet to be established in controlled 
clinical trials.
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Introduction
Cystoid macular edema (CME) is a painless disorder, which affects the central retina or 
macula. Since its first recognition and description in 1974,1 CME has been recognized 
as the most common cause of decreased vision postoperatively in uneventful cataract 
surgery.2 CME is caused by cystic accumulation of intraretinal fluid in the outer 
plexiform and inner nuclear layers of the retina as a result of the breakdown of the 
blood–retinal barrier (Figure 1).3 CME can be a serious consequence of numerous 
ocular procedures and conditions, including cataract surgery, ocular inflammatory 
disease, retinal vascular diseases, and tractional disorders (Table 1).4 It is not a disease 
itself, rather the endpoint of a variety of processes that lead to the accumulation of 
fluid in the central retina.5 Clinical CME has historically been defined as a reduction in 
vision to 20/40 or less that is attributable to ophthalmoscopically or angiographically 
visible CME.6 It can present with symptoms of blurred or decreased central vision, 
and painless retinal inflammation or swelling. In postoperative CME, vision loss is 
usually temporary, with infrequent incidences of permanent visual loss.7 CME is often 
asymptomatic and may only be detected with fluorescein angiography (Figure 2) or 
optical coherence tomography (Figure 1).8 Studies suggest that the rate of clinical 
CME is in the range of 1%–2%,9 whereas the incidence of angiographic CME may 
be as high as 9%–19%.10,11
Uveitic CME, on the other hand, generally has a worse prognosis and the huge 
negative impact of inflammatory CME on visual acuity has become evident in recent 
years. In a large cross-sectional survey of 581 patients with uveitis, 35% of all uveitis eyes 
had a visual acuity of 20/60 or less, of which CME had caused 42%. Clinically significant Journal of Inflammation Research 2009:2 38
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CME developed in 30% of patients with uveitis. Furthermore, 
the authors found that vision loss is especially severe among 
elderly patients and those with chronic disease.12
Pathophysiologic mechanism  
of ocular inflammation and Cme
Arachidonic acid is metabolized by cyclooxygenase to 
prostaglandins which are the most important lipid derived 
mediators of inflammation (Figure 3).13 Surgical trauma causes 
a trigger of the arachidonic acid cascade, which in turn generate 
prostaglandins by activation of cyclooxygenase-1 (COX-1) and 
COX-2. Phospholipids in the cell membrane are the substrate 
for phospholipase A to generate arachidonic acid from which a 
family of chemically distinct prostaglandins and leukotrienes 
are produced.14 Clinical symptoms of prostaglandin production 
include hyperemia, miosis, impaired vision, pain and 
diminished visual acuity secondary to CME.15
Prostaglandin synthesis can be reduced by inhibiting 
phospholipase A2, which inhibits the release of arachidonic 
acid from cell membrane phospholipids, or by inhibiting the 
conversion of arachidonic acid to prostaglandins via the COX 
pathway. Different classes of anti-inflammatory medications 
may block different portions of this pathway. Corticosteroids 
interfere with the activity of phospholipase A2, thereby 
inhibiting the release of arachidonic acid and the production 
of all arachidonic acid metabolites, including prostaglandins.16 
In constrast, nonsteroidal anti-inflammatory drugs (NSAIDs) 
nonspecifically and irreversibly inhibit the synthesis of 
prostaglandins by interfering with the activity of COX-1 and 
COX-2 (Figure 3).16
Most commonly, macular edema results from pathologic 
hyperpermeability of retinal blood vessels, particularly the 
retinal capillary bed. Increased vascular permeability results 
in extravasation of fluid, proteins, and other macromolecules 
into the retinal interstitium.17 Numerous molecules may 
induce the retinal vascular hyperpermeability that leads 
to macular edema. Depending on the underlying disease 
entity, these may include prostaglandins and leukotrienes, 
protein kinase C, nitric oxide, and various cytokines such as 
vascular endothelial growth factor (VEGF), tumor necrosis 
factor α, insulin-like growth factor-1, and interleukins.18–20 
A factor that often contributes to vascular leakage is the 
endothelial damage resulting from leukocyte adherence 
to vessel walls (leukostasis), a phenomenon mediated by 
nitric oxide, adhesion molecules, and other inflammatory 
mediators.20,21
Figure 1 Optical coherence tomography shows intraretinal cystic spaces consistent 
with cystoid macular edema.
Table 1 Pathologic conditions causing macular edema
Inflammatory disorders: intraocular surgery, uveitic syndromes, laser 
procedures
Retinal vascular disease: diabetic retinopathy, retinal vein occlusion, 
hypertensive retinopathy
Choroidal vascular disease: choroidal neovascularization
Tractional maculopathies: epiretinal membrane, vitreomacular  
traction syndromes
Drug reactions: epinephrine, prostaglandin analogs, nicotinic acid, 
tamoxifen, glitazones
Inherited retinal dystrophies: retinitis pigmentosa
Retinal detachment: exudative, rhegmatogenous
Intraocular tumors: choroidal melanoma
Optic nerve head abnormalities: diabetic/hypertensive papillopathy, 
neuroretinitis, optic nerve pits/colobomas
Idiopathic
Figure 2 Fluorescein angiography, right eye.   The recirculation phase of the angiogram 
demonstrates a classic “petalloid” appearance consistent with cystoid macular edema.Journal of Inflammation Research 2009:2 39
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Regardless of the various pathogenic mechanisms causing 
macular edema, the resulting visual acuity depends on many 
factors in addition to macular thickening, including duration 
of edema, perfusion of macular capillaries, photoreceptor 
impairment and/or loss, retinal pigment epithelium (RPE) 
dysfunction, and media opacities.17 It is perhaps not 
surprising that many studies have found poor correlation 
between macular thickness and visual acuity in eyes with 
macular edema of various etiologies.22
Inflammatory conditions causing 
macular edema
Intraocular surgery
CME following cataract surgery (Irvine–Gass syndrome) 
remains the most common cause of visual loss following 
cataract surgery, and a higher incidence is seen when surgery 
is complicated by vitreous loss, vitreous adhesions to the 
cataract wound or other anterior segment structures, iris 
damage, or retained lens material.17 Furthermore, the risk 
of developing postoperative CME is substantially higher 
in patients with pre-exisiting conditions known to produce 
vasoactive stimuli, such as diabetic retinopathy and uveitis.17 
Prostaglandins, as described above, have been implicated in 
causing macular capillary hyperpermeability in this setting.
The risk of pseudophakic CME appears to be lower with 
phacoemulsification surgery than with either extracapsular 
cataract extraction or intracapsular cataract extraction, 
perhaps because of reduced postoperative inflammation.23 
The amount of inflammation, and hence the risk of CME, 
is also greater with higher phaco power (1 J).24 Surgical 
complications dramatically increase the risk of CME. 
A ruptured posterior capsule is associated with an 11.5% 
to 20% incidence of clinical CME in patients undergoing 
phacoemulsification.25,26 Retained lens fragments further 
increase the risk of clinical CME to as much as 29% after 
phacoemulsification.27
Uveitic syndromes
Uveitis can occur in association with autoimmune disorders, 
infection, and exposure to systemic medications or toxins.28 
Uveitis is the fifth most common cause of visual loss in the 
developed world and is estimated to be responsible for up to 
20% of legal blindness worldwide.29 CME is the most frequent 
complication of uveitis and it develops typically in patients with 
intermediate and posterior uveitis components, but may also 
be seen with isolated anterior uveitis, particularly in patients 
positive for human leukocyte antigen (HLA)-B27.17 CME 
may occur in a wide variety of uveitis syndromes, whether 
autoimmune (eg, Pars planitis, birdshot chorioretinitis and Vogt–
Koyanagi–Harada disease), infectious (eg, toxoplasmosis), 
toxic (eg, rifabutin-associated), or idiopathic (eg, sarcoidosis 
and idiopathic vitritis) in etiology.17
Research on CME and ocular inflammatory disease has 
been hampered by the lack of adequate animal models and 
its pathogenesis is not completely understood.30 The most 
important pathogenic mechanism is loss of inner blood–
retinal barrier integrity caused by a variety of inflammatory 
mediators generated by the underlying uveitic process, 
including prostaglandins, leukotrienes, and various cytokines 
such as interleukins, tumor necrosis factor α, and VEGF.19
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Figure 3 Prostaglandin and thromoxane biosynthesis.70   Adapted with permission from FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. 
N Engl J Med. 2001;345(6):433–442.
Abbreviations:  ASA, aspirin; COX, cyclooxygenase; coxibs, COX-2 inhibitors; nSAIDs, nonsteroidal anti-inflammatory drugs; PG, prostaglandin; TxA2, thromboaxane A2.Journal of Inflammation Research 2009:2 40
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The reliable prognostic factors distinguishing CME 
eyes with a potential for improvement from the eyes with 
definitively damaged visual acuity are not yet known. Poor 
contrast sensitivity, impaired color vision, chronicity of 
CME and advanced age of patients were all associated with 
impaired visual outcomes as well as macular ischemia and 
flat optical coherence tomography (OCT) indicating thin and 
atrophic macula.31
Laser procedures
The development of new or worsening macular edema is a 
known complication of panretinal photocoagulation (PRP) for 
retinal vascular disease such as diabetic retinopathy. Although 
the mechanism is not clearly understood, laser-induced 
inflammatory mediators and transudation from increased 
macular blood flow may both play pathogenic roles.17 Focal 
laser photocoagulation prior to or concurrent with PRP 
and dividing the PRP into multiple sessions can decrease 
the incidence of this complication. Approximately 1% of 
patients may develop CME after Nd:YAG capsulotomy.32 
This complication often occurs one to five months later and 
is believed to be related to opening the posterior capsule 
rather than to the energy of the Nd:YAG laser.33
Treatment options for inflammatory 
cystoid macular edema
Initial approach
Anti-inflammatory agents are the mainstay in the treat-
ment of postoperative and uveitic CME. Topical therapy 
with corticosteroid and NSAIDs are commonly used for 
the treatment of macular edema. Corticosteroids (Table 2) 
have been shown to inhibit the inflammatory mediators and 
vascular permeability factors that have been associated with 
macular edema.34–36 Corticosteroids also can retard the loss 
of endothelial tight junction proteins that are important for 
maintaining the blood–retina barrier.37,38
A safer alternative to corticosteroids for the treatment of 
ocular inflammation are the NSAIDs (Table 3), which are 
comprised of several chemically heterogeneous classes of 
drugs which possess potent COX inhibitory activity. Topical 
NSAIDs are classified into six groups based on their chemical 
composition: indoles, phenylacetic acids, phenylalkanoic 
acids, salicylates, fenamates, and pyrazolones. Salicylates, 
fenamates, and pyrazolones are considered too toxic to be 
used in the eye.43,44 Most of the NSAIDs are weakly acidic 
drugs, which ionize at the pH of the lacrimal fluid and 
therefore have limited permeability through the anionic 
cornea which has an isoelectric point pI of 3.2.45 Reducing 
the pH of the formulation increases the unionized fraction of 
the drug which enhances permeation. Being acidic, NSAIDs 
are inherently irritant and reducing the pH of formulation 
further increase their irritation potential, as well as decrease 
their aqueous solubility.46 In addition, the anionic nature 
of NSAIDs lends to the formation of insoluble complexes 
with cationic quaternary ammonium preservatives, such as 
benzalkonium chloride.47,48 Thus, it has proved difficult to 
formulate topical NSAID formulations that are comfortable 
when applied topically to the eye.
Studies comparing NSAIDs with corticosteroids 
have demonstrated no significant difference in the results 
between these treatments.44,53,54 However, NSAID treatment 
appears to be more effective than topical corticosteroids in 
re-establishing the blood aqueous barrier.53,55 Many studies 
that analyzed the effects of NSAIDs on postoperative 
inflammation included the concurrent administration of 
corticosteroids, suggesting that NSAIDs and corticosteroids 
have the potential for synergistic activities.55–57 The beneficial 
effects of NSAIDs over corticosteroids include stabilization 
of intraocular pressure, provision of analgesia and reduction 
of the risk of secondary infections.58
If topical therapy fails
Steroid agents
Resistant cases of postoperative CME and most cases of 
uveitic CME require higher macular concentrations of 
corticosteroid agents, usually achievable with posterior 
sub-Tenon injection.17 Cases further unresponsive to 
sub-Tenon corticosteroid injection may require intraocular 
drug concentrations attainable only with systemic or 
intravitreal delivery. Systemic corticosteroids are typically 
reserved for bilateral CME complicating noninfectious 
uveitis, and should be used with caution given the potential for 
significant systemic complications.17 In active inflammation, 
anti-inflammatory treatment is imperative. A recent OCT 
study documented a more rapid decrease of CME with oral 
administration than with periocular steroid injections, so an 
Table 2 Commercially available topical corticosteroids39–42
Generic Brand Manufacturer Formulation
Difluprednate Durezol Sirion therapeutics 0.05% emulsion
Loteprednol 
etabonate
Lotemax Bausch and Lomb 0.5% suspension
Prednisolone 
acetate
Pred Forte Allergan 1% solution
Rimexolone vexol Alcon 1% suspensionJournal of Inflammation Research 2009:2 41
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initial treatment with oral steroids might be preferred when 
the rapidity of recovery is essential.59
Intravitreal triamcinolone acetonide (IVTA) used in 
variable dosages had a short-term effect on CME and 
improved vision transiently but, despite repeated injections, 
most patients had no sustained improvement of acuity 
compared with baseline.60 The side-effect profile of IVTA is 
significant with corticosteroid-induced intraocular pressure 
rises. The rate of posterior subcapsular cataract formation 
is higher than previously reported, and there is a small but 
potential risk of endophthalmitis.61
Steroid-sparing drugs
In cases of severe uveitis with CME requiring long-term 
treatment with moderate or high doses of corticosteroid, 
the use of steroid-sparing immunosuppressive drugs, 
in collaboration with an internist or rheumatologist, should 
be considered.17 Harding and colleagues evaluated the use 
of intravitreal methotrexate (MTX) to provide an alternative 
for intraocular steroid therapy in patients with unilateral 
intermediate or posterior uveitis and/or CME who are also 
known steroid responders. They found that intravitreal MTX 
can improve visual acuity and reduce CME.62
Intraocular devices
A new treatment approach for patients requiring frequent 
intravitreal  triamcinolone  acetonide  injections  or 
chronic treatment with systemic corticosteroids and/or 
immunosuppressive agents is the use of an intraocular 
steroid sustained-delivery device. An implant containing 
0.59 mg fluocinolone acetonide demonstrated efficacy in 
clinical trials in patients with chronic noninfectious posterior 
uveitis and was recently approved by the US Food and Drug 
Administration (FDA) for this indication.63 The implant 
significantly reduced uveitis recurrences, improved visual 
acuity, and decreased the need for adjunctive therapy. 
However, the fluocinolone acetonide intravitreal implant is 
associated with a high rate of complications such as increased 
intraocular pressure, cataract, retinal detachment (RD), and 
endophthalmitis.63 A large, randomized, controlled clinical 
trial (MUST Trial) sponsored by the US National Eye 
Institute is currently underway comparing the fluocinolone, 
implant with conventional therapy.
The dexamethasone intravitreous drug delivery system 
(DDS) is composed of a biodegradable copolymer of lactic 
acid and glycolic acid. As dexamethasone is released, the 
polymer slowly degrades into carbon dioxide and water. 
Since the implant dissolves completely, sequential implants 
can be placed into they eye over time without the need for 
surgical removal. Dexamethasone DDS was evaluated in 
patients with persistent macular edema resulting from uve-
itis or Irvine–Gass syndrome in a randomized, prospective, 
single-masked controlled trial. The authors found improve-
ments in visual acuity and fluorescein leakage in this sub-
group of patients.64
Antivascular endothelial growth factor, interferons, 
and somatostatin analogues
VEGF is a major regulator of angiogenesis and vascular 
permeability and is strongly implicated in the development 
of CME of various origins. The anti-VEGF drugs inhibit 
the breakdown of the blood-retinal barrier and recent 
data suggest that intravitreal anti-VEGF therapy with 
bevacizumab may be associated with anatomic and visual 
improvement in uveitis patients with CME resistant to 
medical therapy that persists despite control of the uveitis.19 
Unfortunately, the beneficial effect was of short duration. 
These results suggest that, despite its limited inflammatory 
activity, VEGF may play a role in the pathogenesis of uveitic 
CME and that targeting this molecule may potentially be an 
option for treating recalcitrant CME in the setting of uveitis 
remission.
Interferons are implicated in inducing as well as in 
treating autoimmunity and reduced intraocular inflammation, 
especially in Behçet’s disease.65 German studies have shown 
promising results of interferon-α (IFNα) in eight patients 
with CME and inactive uveitis. Side effects of the IFNα 
treatment are frequent and include flu-like symptoms, fatigue, 
hepatotoxicity and psychological disturbances.66 In addition, 
a beneficial effect of IFNβ on uveitic CME was noted in a 
retrospective study of 13 patients with multiple sclerosis-
associated intermediate uveitis.67
Table 3 Commercially available topical NSAIDs49–52
Generic Brand Manufacturer Chemical class Formulation
Ketorolac Acular Allergan Phenylalkanoic acid 0.5% solution
Diclofenac voltaren Novartis Phenylacetic acid 0.1% solution
Nepafenac Nevanac Alcon Arylacetic acid 0.1% suspension
Bromfenac Xibrom Bausch and Lomb Phenylacetic acid 0.09% solutionJournal of Inflammation Research 2009:2 42
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Missotten and colleagues reported on patients with 
persisting macular edema in uveitis in an otherwise quiescent 
eye and found that the somatostatin analog octreotide long-
acting repeatable (LAR) had an edema-reducing effect in 
70% of treated CME episodes. Successful response was 
related to duration of CME before start of treatment.68
Surgical treatment
Vitrectomy surgery has a role in the management of selected 
patients with chronic inflammatory CME. In eyes with 
chronic CME and vitreous adhesions to anterior segment 
structures following complicated cataract surgery, vitrectomy 
with removal of all vitreous adhesions generally results in 
anatomic and visual benefit.69 The current literature contains 
no convincing data that vitrectomy favorably modifies the 
course of CME in patients with chronic, recurrent uveitis.
Conclusion
Macular edema is a condition of enormous medical and 
socioeconomic importance because of its high prevalence and 
occurrence in a large number of pathologic conditions. It is 
the endpoint of a variety of pathophysiologic processes that 
can be effectively managed by recognizing and addressing 
the pathogenic factors that are operative in a given clinical 
setting. So far, there are no clear guidelines for the treatment 
of subclinical cystoid macular edema and every practitioner 
has their own strategy using a variety of pharmacologic 
agents, as well as vitreous surgery when needed. Although 
treatment options continue to expand with the development 
of new drugs and surgical procedures, long-term efficacy and 
safety of most new approaches have yet to be established in 
controlled clinical trials.
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